Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF 83 Equity-to-Asset is 0.84 as of Mar. 2026, which is 9% above its 10-year median of 0.77. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.54 (Fairly Valued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Covalon Technologies ranks better than 81.36% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Covalon Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $20.42 Mil. Covalon Technologies's Total Assets for the quarter that ended in Mar. 2026 was $24.18 Mil.
Therefore, Covalon Technologies's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.84.
The historical rank and industry rank for Covalon Technologies's Equity-to-Asset or its related term are showing as below:
CVALF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25 Med: 0.77 Max: 0.89
Current: 0.84
During the past 13 years, the highest Equity to Asset Ratio of Covalon Technologies was 0.89. The lowest was 0.25. And the median was 0.77.
CVALF's Equity-to-Asset is ranked better than 81.36% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs CVALF: 0.84
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Covalon Technologies Equity-to-Asset Related Terms
Covalon Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Covalon Technologies's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies (CVALF) has a Equity-to-Asset of 0.84 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Covalon Technologies and its competitors. This is near median its historical median of 0.77. Over the past decade, Covalon Technologies' Equity-to-Asset has ranged from 0.25 to 0.89. According to the industry distribution chart, Covalon Technologies ranks #159 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 18.6%.
Is Covalon Technologies' Equity-to-Asset too high?
Covalon Technologies' current Equity-to-Asset of 0.84 is near median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.89. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Covalon Technologies' value of 0.84 is 29.2% above this industry median. Based on the distribution chart, Covalon Technologies ranks #159 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #159 out of 853 companies for Equity-to-Asset. This places Covalon Technologies in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.65. Covalon Technologies' value of 0.84 is 29.2% above this benchmark. Historically, Covalon Technologies' own Equity-to-Asset has ranged from 0.25 to 0.89 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.65, Covalon Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Equity-to-Asset of 0.84 is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Equity-to-Asset is 0.84, which is near median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.47 — trading 4.7% below its estimated fair value. The current Equity-to-Asset is 0.84, which is near median its 10-year median of 0.77 and 29.2% above the Medical Devices & Instruments industry median of 0.65. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Equity-to-Asset is 0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.47 is trading 4.7% below its estimated GF Value™ of $1.54.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Equity-to-Asset: 0.84 (near median its 10-year median of 0.77)
GF Value™: $1.54 vs. price of $1.47 (4.7% below fair value)
Industry Position: 29.2% above the Medical Devices & Instruments median (#159 of 853)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
